Premium
Hydroxyurea treatment for chronic myeloid leukaemia during pregnancy
Author(s) -
Jackson Nicholas,
Shukri Ahmad,
Ali Kamaruzaman
Publication year - 1993
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.1993.tb08672.x
Subject(s) - medicine , pregnancy , hydroxycarbamide , chronic myeloid leukaemia , blood count , white blood cell , abnormality , myeloid , pediatrics , chemotherapy , biology , genetics , psychiatry
Summary. A patient being treated for chronic myeloid leukaemia with hydroxyurea became pregnant. Despite an increase in the dose of hydroxyurea (to 3 g per day) during the pregnancy, her white blood cell count could only be controlled at about 150 × 10 9 /l. A healthy baby girl was born at 3 7 weeks with normal blood counts and no evidence of congenital abnormality. There are now five reports of the use of hydroxyurea in pregnancy, and where leucapheresis is not available it may be the treatment of choice.